Recruiting Studies
Advanced SearchData: ClinicalTrials.gov · Source of record for eligibility and locations
Top Cities for Amyloidosis Clinical Trials
Amyloidosis clinical trials are recruiting across 68 cities. Here are the cities with the most active studies:
Amyloidosis Trial Phases
27 research organizations are sponsoring amyloidosis trials.
About Amyloidosis
Amyloidosis is a group of diseases in which abnormal proteins (amyloids) build up in organs and tissues, impairing their function. Types include AL, AA, and ATTR amyloidosis. Treatment depends on the type and may include chemotherapy, organ transplant, or targeted therapies.
Clinical trials are advancing new treatments for amyloidosis. Currently, 43 studies are recruiting a combined 75,076 participants across the United States. Research is being conducted by 27 organizations including AstraZeneca, Ohio State University Comprehensive Cancer Center, Idoven 1903 S.L. and 24 others.
2026 Amyloidosis Research Landscape
As of July 2026, the amyloidosis clinical trial landscape includes 43 actively recruiting studies across 68 cities in the United States. These studies are collectively seeking 75,076 participants, with an average enrollment target of 1,746 per study.
The research spans multiple phases of development: 12 studies are in PHASE2, 7 studies are in PHASE3, 7 studies are in NA, 7 studies are in PHASE1, 1 study is in PHASE4. The presence of Phase 3 trials indicates that some amyloidosis treatments are in late-stage testing and may be approaching regulatory review.
Research is being led by 27 different organizations, including AstraZeneca, Ohio State University Comprehensive Cancer Center, Idoven 1903 S.L., Alnylam Pharmaceuticals, Columbia University, and 22 others. The large number of sponsors reflects significant research interest and investment in amyloidosis treatment advancement.
Geographically, amyloidosis trials are most concentrated in Boston, Massachusetts (16 trials); New York, New York (10 trials); Los Angeles, California (8 trials); Rochester, Minnesota (8 trials); San Francisco, California (7 trials) and 7 other cities.
Featured Amyloidosis Studies
Highlighted recruiting studies for amyloidosis, selected by enrollment size and research scope.
OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
The overall aim of this observational study is to generate real-world evidence on the pre- and post-diagnosis disease journeys, including baseline characteristics, treatment patterns and selected clinical, economic, and humanistic outcomes (for example Health Related Quality of Life (HRQoL), Neuropathy impairment score, activities of daily living (ADL) assessments) in patients with ATTR amyloidosi...
Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
The investigators are researching patients with diseases of their plasma cells in order to improve their quality and length of life. The investigators have created a database of patient information, blood samples, and bone marrow tissue in order to achieve the following three goals: * Surveillance: The investigators want to track what treatments patients get or don't get, how effective they are, ...
Multicenter Study for the Validation of an AI-based ECG Platform for Early Cardiac Amyloidosis Diagnosis
CONCERTO is a retrospective, observational, multicentric and single-arm study to perform an external validation of the cloud-based and AI-powered electrocardiogram (ECG) analysis platform, named Willem™, to detect Transthyretin cardiac amyloidosis (ATTR-CA). Thus, this study will assess Willem™ ability to distinguish between truly diagnosed ATTR-CA patients and confirmed non-ATTR-CA patients from ...
Frequently Asked Questions About Amyloidosis Clinical Trials
Are there amyloidosis clinical trials near me?
Yes, there are 43 amyloidosis clinical trials currently recruiting across 68+ cities in the United States, including Boston, Massachusetts; New York, New York; Los Angeles, California. Browse the studies above to find one at a location convenient for you.
How do I join a amyloidosis clinical trial?
To join a amyloidosis clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are amyloidosis clinical trials free?
Yes, participation in amyloidosis clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of amyloidosis treatments are being studied?
Current amyloidosis clinical trials are testing a range of approaches across PHASE2 (12 studies), PHASE3 (7 studies), NA (7 studies), PHASE1 (7 studies), PHASE4 (1 study). These include new drugs, combination therapies, medical devices, and other interventions sponsored by 27 research organizations.
Is it safe to participate in amyloidosis clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated July 16, 2026 from ClinicalTrials.gov
About This Data
Data: ClinicalTrials.gov · Source of record for eligibility and locations
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated July 16, 2026 · Data from ClinicalTrials.gov